Marstacimab trial for children with hemophilia A or B
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This Phase 3 study tests marstacimab, a new medicine, to help prevent or better control bleeding in children and teens with hemophilia A or hemophilia B. You may be eligible if your child’s past records show ongoing bleeding and treatment with factor replacement (or specific inhibitor-related patterns).
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is male and within the study ages: 12–17 (≥25 kg) or 6–11 (≥19 kg)
- Your child has severe hemophilia A or moderately severe to severe hemophilia B
- There are at least 1 year of consistent records showing factor replacement (FVIII/FIX) or bypass infusions plus bleeding episodes
- If in the Non-Inhibitor group: no current inhibitor and no inhibitor history for the last 5 years
- If in the Inhibitor group: they currently have an inhibitor pattern or frequent bleeding needing bypass treatment (details must match exactly)
- They are not using certain other hemophilia medicines (like emicizumab or gene therapy) or specific immune medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study looks at how well and how safely marstacimab works over a longer follow-up period. You may join if you already finished a related parent study for hemophilia, and you can keep up with frequent visits and lab tests.
This study watches how well damoctocog alfa pegol (a medicine to help blood clot) works in children with hemophilia A. It is for kids ages 7 to 12 who have used factor VIII before and do not have inhibitors (antibodies that stop the medicine from working).
This trial tests a gene therapy to help your body produce more of the clotting protein (factor VIII) it's missing. It may reduce or stop the need for regular factor infusions.
This trial tests emicizumab, a medicine given under the skin, to see how it works in children with hemophilia A. It aims to help control bleeding, no matter if they have inhibitors or not.
This Phase 1 study tests a one-time gene therapy treatment (BBM-H901) for boys ages 12 to 18 with hemophilia B. It aims to see if the treatment is safe and can help the body make more clotting factor over time.
This trial tests a single dose of CSL222, a gene therapy, in adolescent boys with severe or moderately severe hemophilia B. The goal is to see if it can reduce or eliminate the need for regular factor IX infusions.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.